NCT06197581View on ClinicalTrials.gov

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

January 12, 2024

Primary Completion Date

January 15, 2026

Study Completion Date

January 15, 2027

Conditions
Breast Cancer, Familial MaleRadiotherapy; ComplicationsChemotherapeutic ToxicityImmune Checkpoint InhibitorCDK4/6 InhibitorTrastuzumabPertuzumabPARP Inhibitor
Interventions
RADIATION

Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)

Patients will receive chest wall / breast radiation with or without lymph node region radiation and novel drugs(for specific population according to guidelines) concurrently.

Trial Locations (1)

100021

RECRUITING

Cancer Hospital ,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER